Rapport Therapeutics, Inc./$RAPP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Ticker
$RAPP
Sector
Primary listing
Employees
69
Headquarters
Website
RAPP Metrics
BasicAdvanced
$613M
-
-$2.51
-
-
Price and volume
Market cap
$613M
52-week high
$17.76
52-week low
$6.43
Average daily volume
174K
Financial strength
Current ratio
22.75
Quick ratio
21.925
Long term debt to equity
3.834
Total debt to equity
4.502
Profitability
EBITDA (TTM)
-100.79
Management effectiveness
Return on assets (TTM)
-20.14%
Return on equity (TTM)
-29.42%
Valuation
Price to book
2.33
Price to tangible book (TTM)
2.33
Price to free cash flow (TTM)
-7.704
Free cash flow yield (TTM)
-12.98%
Free cash flow per share (TTM)
-2.181
Growth
Earnings per share change (TTM)
-84.16%
RAPP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rapport Therapeutics, Inc. stock?
Rapport Therapeutics, Inc. (RAPP) has a market cap of $613M as of August 29, 2025.
What is the P/E ratio for Rapport Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Rapport Therapeutics, Inc. (RAPP) stock is 0 as of August 29, 2025.
Does Rapport Therapeutics, Inc. stock pay dividends?
No, Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders as of August 29, 2025.
When is the next Rapport Therapeutics, Inc. dividend payment date?
Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders.
What is the beta indicator for Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc. (RAPP) does not currently have a Beta indicator.